Repotrectinib
- Generic Name
- Repotrectinib
- Drug Type
- Small Molecule
- Chemical Formula
- C18H18FN5O2
- CAS Number
- 1802220-02-5
- Unique Ingredient Identifier
- 08O3FQ4UNP
- Indication
用于ROS1阳性的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
- Target Recruit Count
- 30
- Registration Number
- NCT06552234
- Locations
- 🇫🇷
CH Aix-en-Provence, Aix-en-Provence, Bouches Du Rhône, France
🇫🇷AP-HM, Marseille, Bouches Du Rhône, France
🇫🇷HIA Sainte Anne, Toulon, Var, France
A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT06493409
- Locations
- 🇺🇸
Fortrea - Daytona Beach, Daytona Beach, Florida, United States
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negativeMetastatic Invasive LObular Carcinoma
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT06408168
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT06352528
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Local Institution - 0005, Orlando, Florida, United States
🇺🇸Local Institution - 0006, Miami Lakes, Florida, United States
REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
- Conditions
- NSCLCBrain MetastasesROS1 Gene Rearrangement
- Interventions
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 20
- Registration Number
- NCT06315010
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
🇪🇸Hospital Clínico Universitario de Valencia, Valencia, Spain
🇪🇸Hospital General Universitario Dr. Balmis, Alicante, Spain
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 190
- Registration Number
- NCT06140836
- Locations
- 🇺🇸
Local Institution - 0136, Augusta, Georgia, United States
🇺🇸Local Institution - 0221, Des Moines, Iowa, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Expanded Access for Repotrectinib
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05926232
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05828303
- Locations
- 🇺🇸
Local Institution - 2101, Canton, Ohio, United States
🇺🇸Gabrail Cancer Research Center, Canton, Ohio, United States
🇦🇺Local Institution - 2119, Westmead, New South Wales, Australia
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Registration Number
- NCT05828277
- Locations
- 🇪🇸
Local Institution - 4103, Madrid, Spain
🇺🇸Gabrail Cancer Research Center, Canton, Ohio, United States
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
- Conditions
- KRAS Mutation-Related TumorsAdvanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05071183
- Locations
- 🇺🇸
Local Institution - 2107, Houston, Texas, United States
🇺🇸Local Institution - 2102, Virginia Beach, Virginia, United States
🇺🇸Local Institution - 2101, California City, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.